Insider · CIK 0001262326

Mirabelli Christopher

CIK 0001262326 Name as filed on the most recent filing

Filed as Mirabelli Christopher (15)· Miraelli Christopher (3)

23 transaction lines · from 18 filings · filed 2004-06-02 to 2026-03-30 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

6 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-03-26 S, Open-market sale Cypherpunk Technologies Inc.CYPH 42,630, disposed Open Form 4 filing 0001104659-26-036804
2025-11-17 S, Open-market sale Cypherpunk Technologies Inc.CYPH 2 lines 2,123,642, disposed Open Form 4 filing 0001104659-25-114094
2019-02-05 P, Open-market purchase Leap Therapeutics, Inc.LPTX 999,999, acquired Open Form 4 filing 0001104659-19-005836
2017-11-14 P, Open-market purchase Leap Therapeutics, Inc.LPTX 6,436,524, acquired Open Form 4 filing 0001104659-17-069117
2016-02-19 S, Open-market sale Globeimmune IncGBIM 6,950, disposed Open Form 4 filing 0001209191-16-100441
2016-02-18 S, Open-market sale Globeimmune IncGBIM 7,000, disposed Open Form 4 filing 0001209191-16-100441
2016-02-17 S, Open-market sale Globeimmune IncGBIM 7,650, disposed Open Form 4 filing 0001209191-16-100441
2016-02-17 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 3,000,000, acquired Open Form 4 filing 0000899243-16-013608
2016-02-16 S, Open-market sale Globeimmune IncGBIM 7,550, disposed Open Form 4 filing 0001209191-16-098769
2016-02-12 S, Open-market sale Globeimmune IncGBIM 7,950, disposed Open Form 4 filing 0001209191-16-098769
2016-02-11 S, Open-market sale Globeimmune IncGBIM 8,600, disposed Open Form 4 filing 0001209191-16-098769
2014-07-08 P, Open-market purchase Globeimmune IncGBIM 1,900,000, acquired Open Form 4 filing 0001209191-14-046450
2014-02-05 P, Open-market purchase Trevena IncTRVN 2,079,406, acquired Open Form 4 filing 0001209191-14-008252
2013-12-17 P, Open-market purchase Tetralogic Pharmaceuticals CorpTLOG 4,994,241, acquired Open Form 4 filing 0001209191-13-057535
2009-10-05 P, Open-market purchase Threshold Pharmaceuticals IncTHLD Not reported Open Form 4 filing 0001209191-09-048013
2007-08-03 P, Open-market purchase Pharmathene, IncHAQ 957,500, acquired Open Form 4 filing 0001231919-07-000111
2007-08-03 P, Open-market purchase Healthcare Acquisition CorpHAQ 957,500, acquired Open Form 4 filing 0001231919-07-000065
2007-08-03 P, Open-market purchase Activbiotics IncHAQ 957,500, acquired Open Form 4 filing 0001231919-07-000064
2007-04-12 P, Open-market purchase Advancis Pharmaceutical CorpAVNC 1,614,178, acquired Open Form 4 filing 0001231919-07-000029
2005-06-20 P, Open-market purchase Critical Therapeutics IncCRTX 6,000,003, acquired Open Form 4 filing 0001231919-05-000050
2004-06-02 P, Open-market purchase Critical Therapeutics IncCRTX 2,499,700, acquired Open Form 4 filing 0001231919-04-000200
2004-06-02 P, Open-market purchase Critical Therapeutics IncCRTX 2,499,700, acquired Open Form 4 filing 0001231919-04-000175

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 3
  • Open-market sale 3
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Mirabelli Christopher, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001262326

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.